

Sub E1
derived from the subject, wherein the LSD marker is selected from the group consisting of Lamp-1 (lysosome-associated membrane protein type-1), 4-sulphatase, and β -hexosaminidase, an increase in the level of the LSD marker in the subject relative to the corresponding level of the LSD marker in a non-affected individual or population being indicative of a LSD.

E2 Sub 92
55. (Twice amended) The method according to claim 52, wherein the LSD marker is Lamp-1.

E3
59. (Once amended) The method according to claim 55, wherein the biological sample comprises blood, plasma, urine, a fibroblast cell, a fibroblast cell culture or a fibroblast cellular extract.

E4
68. (Twice amended) The method according to claim 66, wherein the one or more antibodies are monoclonal antibodies.

REMARKS

I. Status of the Claims

Claims 52, 55, 58-66, 68-74 and 93 are pending in this application. Claims 52, 55, 59, and 68 are been amended without prejudice or disclaimer upon entry of this amendment.

II. Rejection under 35 U.S.C. 112, first paragraph

Claims 52, 58-66 and 69-73 stand rejected as not being enabled when the LSD marker is α -mannosidase. While not agreeing with this conclusion, claim 52 has been amended to delete reference to this marker to advance prosecution of important subject matter. This amendment renders this ground of rejection moot.

III. Rejection under 35 U.S.C. 102

Claims 52, 58, 60, 63-64 and 66 are rejected as being anticipated by an article to Chamberlin et al. (Clinical Chem. 41:1495-1499, 1995) because of its discussion of tartrate resistant acid phosphatase in certain patients with Gaucher disease. In order to advance